CoreCap Advisors’s Microbot Medical MBOT Stock Holding History

CoreCap Advisors’s Portfolio MBOT Stock Details MBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-50	Closed	–	–	1433
2022 Q2	$0	Buy	+50	New	+$278	﹤0.01%	2218
2022 Q1	–	Sell	-50	Closed	-$1K	–	1430
2021 Q4	$1K	Buy	+50	New	+$322	﹤0.01%	2179

Other funds holding MBOT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AlphaCentric Advisors San Juan, Puerto Rico $100M AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CAN

Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

CoreCap Advisors's MBOT Position: Q3 2022 in Review

CoreCap Advisors sold out of Microbot Medical (MBOT) in Q3 2022, closing a stake of 50 shares.

CoreCap Advisors first reported a position in MBOT in Q4 2021 and held it in 2 quarters. The position peaked at $1K in Q4 2021. 23 funds tracked by Wall St. Rank hold MBOT as of Q3 2022.

CoreCap Advisors reported no remaining Microbot Medical position as of Q3 2022 after selling out during the quarter.
CoreCap Advisors sold 50 Microbot Medical shares in Q3 2022.
CoreCap Advisors first reported a position in Microbot Medical in Q4 2021 and held it in 2 quarters.
CoreCap Advisors's Microbot Medical position peaked at $1K in Q4 2021.
23 funds tracked by Wall St. Rank held Microbot Medical as of Q3 2022.

Based on CoreCap Advisors's 13F filing for Q3 2022, filed 10 Feb 2023.